{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:47:33Z","timestamp":1787068053368,"version":"build-2736575974"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004263","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado do Rio Grande do Sul","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004263","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["306606\/2017\u20138"],"award-info":[{"award-number":["306606\/2017\u20138"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["402318\/2016\u20131"],"award-info":[{"award-number":["402318\/2016\u20131"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["12\/2017"],"award-info":[{"award-number":["12\/2017"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ejmech.2018.08.079","type":"journal-article","created":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T02:30:34Z","timestamp":1535682634000},"page":"1426-1459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Synthesis and structure-activity relationship studies of cruzain and rhodesain inhibitors"],"prefix":"10.1016","volume":"157","author":[{"given":"D\u00e9bora A.","family":"Rocha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elany B.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isadora S.","family":"Fortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela S.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaela S.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2873-7939","authenticated-orcid":false,"given":"Saulo F.","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2018.08.079_bib1","author":"World Health Organization"},{"key":"10.1016\/j.ejmech.2018.08.079_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0005979","article-title":"A\u00a0polymorphism in the haptoglobin, haptoglobin related protein locus is associated with risk of human sleeping sickness within Cameroonian populations","volume":"11","author":"Ofon","year":"2017","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2018.08.079_bib3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2174\/1381612023396177","article-title":"Chemotherapy of Chagas disease","volume":"8","author":"Urbina","year":"2002","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2018.08.079_bib4","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1038\/nature09224","article-title":"Chagas disease: pushing through the pipeline","volume":"465","author":"Clayton","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2018.08.079_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1021\/jm901069a","article-title":"Identification and optimization of inhibitors of Trypanosomal cystein proteases: cruzain, rhodesian, and TbCatB","volume":"53","author":"Mott","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib6","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/978-1-4419-8414-2_7","article-title":"CRUZAIN: The path from target validation to the clinic","volume":"712","author":"Sajid","year":"2011","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejmech.2018.08.079_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actatropica.2015.12.017","article-title":"Current drug therapy and pharmaceutical challenges for Chagas disease","volume":"156","author":"Bermudez","year":"2016","journal-title":"Acta Trop."},{"key":"10.1016\/j.ejmech.2018.08.079_bib8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0035-9203(40)90088-8","article-title":"Concentration of Bayer 205 (Germanin) in human blood and cerebrospinal fluid after treatment","volume":"34","author":"Hawking","year":"1940","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.ejmech.2018.08.079_bib9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drup.2007.02.004","article-title":"Drugs and drug resistance in African trypanosomiasis","volume":"10","author":"Delespaux","year":"2007","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.ejmech.2018.08.079_bib10","first-page":"1","article-title":"Trypanocidal drugs: mechanisms, resistance and new targets","volume":"11","author":"Wilkinson","year":"2009","journal-title":"Expet Rev. Mol. Med."},{"key":"10.1016\/j.ejmech.2018.08.079_bib11","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0968-0896(99)00008-5","article-title":"Cysteine protease inhibitors as chemotherapy for parasitic infections","volume":"7","author":"McKerrow","year":"1999","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib12","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.2174\/1381612013397528","article-title":"The major cysteine proteinase of Trypanosoma cruzi: a valid target for chemotherapy of Chagas Disease","volume":"7","author":"Cazzulo","year":"2001","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2018.08.079_bib13","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/j.1365-2958.2007.05970.x","article-title":"Role of the Trypanosoma brucei natural cysteine peptidase inhibitor ICP in differentiation and virulence","volume":"66","author":"Santos","year":"2007","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.ejmech.2018.08.079_bib14","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/jmbi.1994.0137","article-title":"The crystal structure of cruzain: a therapeutic target for Chagas' disease","volume":"247","author":"McGrath","year":"1995","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2018.08.079_bib15","doi-asserted-by":"crossref","first-page":"25697","DOI":"10.1074\/jbc.M109.014340","article-title":"Vinyl sulfones as antiparasitic agents and a structural basis for drug design","volume":"284","author":"Kerr","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib16","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0022-3565(24)37785-7","article-title":"Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A,P-Glycoprotein dual substrate, in male sprague-dawley rats","volume":"287","author":"Zhang","year":"1998","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2018.08.079_bib17","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1128\/AAC.00436-07","article-title":"A\u00a0cysteine protease inhibitor cures Chagas Disease in an immunodeficient-mouse model of infection","volume":"51","author":"Doyle","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.08.079_bib18","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1021\/jm010459j","article-title":"Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruzain","volume":"45","author":"Du","year":"2002","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib19","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1021\/jm030549j","article-title":"Synthesis and structure-activity relationships of parasiticidal thiosemicarbazone cysteine protease inhibitors against Plasmodium falciparum, Trypanosoma brucei and Trypanosoma cruzi","volume":"47","author":"Greenbaum","year":"2004","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib20","unstructured":"E.R. Hickey, Y. Bekkali, U.R. Patel, D.M. Spero, D.S. Thomson, E.R.R. Young, Nitriles useful as reversible inhibitors of cysteine proteases, U.S. Patent 6,982,263, Jan 3, 2006."},{"key":"10.1016\/j.ejmech.2018.08.079_bib21","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/cmdc.201300112","article-title":"Optimization of triazine nitriles as rhodesain inhibitors: structure-activity relationships, bioisosteric imidazopyridine nitriles, and X-ray crystal structure analysis with human cathepsin L","volume":"8","author":"Ehmke","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2018.08.079_bib22","doi-asserted-by":"crossref","first-page":"6697","DOI":"10.1016\/j.bmcl.2007.10.056","article-title":"Dipeptidyl-alpha,beta-epoxyesters as potent irreversible inhibitors of the cysteine proteases cruzain and rhodesain","volume":"17","author":"Gonz\u00e1lez","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.08.079_bib23","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1002\/cmdc.201300390","article-title":"Development of rhodesain inhibitors with a 3-bromoisoxazoline warhead","volume":"8","author":"Ettari","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2018.08.079_bib24","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.bmc.2017.02.009","article-title":"Synthesis and biological evaluation of potential inhibitors of the cysteine proteases cruzain and rhodesain designed by molecular simplification","volume":"25","author":"Braga","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib25","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1021\/jm401709b","article-title":"Synthesis, biological evaluation, and Structure\u2212Activity relationships of potent noncovalent and nonpeptidic cruzain inhibitors as anti-trypanosoma cruzi agents","volume":"57","author":"Ferreira","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib26","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S0020-7519(99)00044-2","article-title":"Development of cysteine protease inhibitors as chemotherapy for parasitic diseases: insights on safety, target validation, and mechanism of action","volume":"29","author":"McKerrow","year":"1999","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.ejmech.2018.08.079_bib27","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.drudis.2015.02.004","article-title":"Cruzain inhibitors: efforts made, current leads and a structural outlook of new hits","volume":"20","author":"Martinez-Mayorga","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2018.08.079_bib28","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.2174\/1389557515666160509125243","article-title":"The inhibition of cysteine proteases rhodesain and TbCatB: a valuable approach to treat human African Trypanosomiasis","volume":"16","author":"Ettari","year":"2016","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.pharmthera.2017.06.004","article-title":"Targeting cysteine proteases in trypanosomatid disease drug discovery","volume":"180","author":"Ferreira","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2018.08.079_bib30","series-title":"Comprehensive Analysis of Parasite Biology: from Metabolism to Drug Discovery","first-page":"121","article-title":"Trypanosomal cysteine peptidases: target validation and drug design strategies","author":"Da Silva","year":"2016"},{"key":"10.1016\/j.ejmech.2018.08.079_bib31","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1016\/S0960-894X(01)00566-2","article-title":"Potent second generation vinyl sulfonamide inhibitors of the trypanosomal cysteine protease cruzain","volume":"11","author":"Roush","year":"2001","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib32","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1084\/jem.188.4.725","article-title":"Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection","volume":"188","author":"Engel","year":"1998","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ejmech.2018.08.079_bib33","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1128\/AAC.49.12.5160-5161.2005","article-title":"A\u00a0cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi","volume":"49","author":"Barr","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.08.079_bib34","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1021\/jm00017a002","article-title":"Vinyl Sulfones as mechanism-based cysteine protease inhibitors","volume":"38","author":"Palmer","year":"1995","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib35","first-page":"360","article-title":"Overlapping susbtrate specifities of cytochrome P450 3a and P-glycoprotein for a novel cysteine protease inhibitor","volume":"26","author":"Zhang","year":"1998","journal-title":"ASPET Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2018.08.079_bib36","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1242\/jcs.111.5.597","article-title":"Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi","volume":"111","author":"Engel","year":"1998","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.ejmech.2018.08.079_bib37","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S0090-9556(24)15083-0","article-title":"In\u00a0vitro evaluation of the disposition of a novel cysteine protease inhibitor","volume":"28","author":"Jacobsen","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2018.08.079_bib38","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/S0968-0896(98)80022-9","article-title":"Structure-based design, synthesis and evaluation of conformationally constrained cysteine protease inhibitors","volume":"6","author":"Scheidt","year":"1998","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib39","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1021\/ol034555l","article-title":"Relative rates of Michael reactions of 2\u2032-(phenethyl)thiol with vinyl Sulfones,Vinyl sulfonate esters, and vinyl sulfonamides relevant to vinyl sulfonyl cysteine protease inhibitors","volume":"5","author":"Reddick","year":"2003","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2018.08.079_bib40","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.bmcl.2007.11.070","article-title":"Potency and selectivity of P2\/P3-modified inhibitors of cysteine proteases from trypanosomes","volume":"18","author":"Jaishankar","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.08.079_bib41","doi-asserted-by":"crossref","first-page":"5860","DOI":"10.1016\/j.bmcl.2008.06.012","article-title":"Synthesis of macrocyclic trypanosomal cysteine protease inhibitors","volume":"18","author":"Chen","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.08.079_bib42","doi-asserted-by":"crossref","first-page":"6218","DOI":"10.1016\/j.bmcl.2009.08.098","article-title":"Novel non-peptidic vinylsulfones targeting the S2 and S3 subsites of parasite cysteine proteases","volume":"19","author":"Bryant","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.08.079_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0000825","article-title":"In\u00a0Vitro and in\u00a0Vivo studies of the trypanocidal properties of WRR-483 against Trypanosoma cruzi","volume":"4","author":"Chen","year":"2010","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2018.08.079_bib44","doi-asserted-by":"crossref","first-page":"6638","DOI":"10.1021\/jm400294w","article-title":"Vinyl sulfone-based peptidomimetics as anti-trypanosomal agents: design, synthesis, biological and computational evaluation","volume":"56","author":"Dunny","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib45","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.1039\/C4OB01412J","article-title":"Preparation, anti-trypanosomal activity and localisation of a series of dipeptide-based vinyl sulfones","volume":"12","author":"Doherty","year":"2014","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib46","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/cmdc.201500204","article-title":"Dipeptidyl enoates as potent rhodesain inhibitors that display a dual mode of action","volume":"10","author":"Royo","year":"2015","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2018.08.079_bib47","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1016\/j.bmcl.2015.08.074","article-title":"Identification of non-peptidic cysteine reactive fragments as inhibitors of cysteine protease rhodesain","volume":"25","author":"McShan","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.08.079_bib48","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1021\/acsmedchemlett.5b00336","article-title":"Synthesis and evaluation of oxyguanidine analogues of the cysteine protease inhibitor WRR-483 against cruzain","volume":"7","author":"Jones","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.08.079_bib49","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1021\/acsmedchemlett.6b00276","article-title":"Dipeptidyl nitroalkenes as potent reversible inhibitors of cysteine proteases rhodesain and cruzain","volume":"7","author":"Latorre","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.08.079_bib50","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1128\/AAC.04601-14","article-title":"Synthesis of a sugar-based thiosemicarbazone series and structure-activity relationship versus the parasite cysteine proteases rhodesain, cruzain, and Schistosoma mansoni cathepsin B1","volume":"59","author":"Fonseca","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.08.079_bib51","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.ejmech.2015.06.048","article-title":"Synthesis and structure-activity relationship study of a new series of antiparasitic aryloxyl thiosemicarbazones inhibiting Trypanosoma cruzi cruzain","volume":"101","author":"Esp\u00edndola","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib52","doi-asserted-by":"crossref","first-page":"6818","DOI":"10.1016\/j.bmc.2011.09.037","article-title":"Thiosemicarbazones derived from 1-indanones as new anti-Trypanosoma cruzi agentes","volume":"19","author":"Caputto","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib53","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bmcl.2004.10.023","article-title":"Discovery of potent thiosemicarbazone inhibitors of rhodesain and cruzain","volume":"15","author":"Fujii","year":"2005","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.08.079_bib54","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3390\/81100793","article-title":"The chemistry of \u03b1-haloketones and their utility in heterocyclic synthesis","volume":"8","author":"Erian","year":"2003","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2018.08.079_bib55","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejmech.2017.02.026","article-title":"Desing and synthesis of potent anti-Trypanosoma cruzi agents new thiazoles derivatives which induce apoptotic parasite death","volume":"130","author":"Da Silva","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib56","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ejmech.2016.05.050","article-title":"New 1,3-thiazole derivatives and their biological and ultrastructural effects on Trypanosoma cruzi","volume":"121","author":"Gomes","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib57","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ejmech.2017.09.047","article-title":"Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi","volume":"141","author":"De Oliveira Filho","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib58","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ejmech.2017.09.039","article-title":"2-Aminothiophene scaffolds: diverse biological and pharmacological attributes in medicinal chemistry","volume":"140","author":"Bozorov","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib59","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1016\/j.bmc.2016.07.013","article-title":"Design, synthesis, molecular docking and biological evaluation of thiophen-2-iminothiazolidine derivatives for use against Trypanosoma cruzi","volume":"24","author":"Silva-J\u00fanior","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib60","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1002\/cmdc.201300390","article-title":"Development of rhodesain inhibitors with a 3-bromoisoxazoline warhead","volume":"8","author":"Ettari","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2018.08.079_bib61","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1021\/jo00036a013","article-title":"Nitrile oxides in medicinal chemistry. 4. Chemoenzymic synthesis of chiral heterocyclic derivatives","volume":"57","author":"De Amici","year":"1992","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib62","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1002\/ejoc.200600628","article-title":"Synthesis of 3-hydroxy- and 3-carboxy-\u00c42-isoxazoline amino acids and evaluation of their interaction with GABA receptors and transporters","volume":"2006","author":"Conti","year":"2006","journal-title":"Eur. J. Org Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib63","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3109\/14756366.2015.1108972","article-title":"Synthesis and biological evaluation of novel peptidomimetics as rhodesain inhibitors","volume":"31","author":"Ettari","year":"2016","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib64","doi-asserted-by":"crossref","first-page":"7053","DOI":"10.1016\/j.bmc.2015.09.029","article-title":"Development of novel dipeptide-like rhodesain inhibitors containing the 3-bromoisoxazoline warhead in a constrained conformation","volume":"23","author":"Ettari","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib65","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1021\/jm060405f","article-title":"Novel peptidomimetic cysteine protease inhibitors as potential antimalarial agents","volume":"49","author":"Micale","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib66","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0304-4165(90)90174-U","article-title":"Reversible covalent binding of peptide nitriles to papain","volume":"1035","author":"Hanzlik","year":"1990","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2018.08.079_bib67","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1021\/jm010206q","article-title":"Identification of dipeptidyl nitriles as potent and selective inhibitors of cathepsin B through structure-based drug design","volume":"44","author":"Greenspan","year":"2001","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib68","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1016\/j.bmcl.2003.08.006","article-title":"N-arylaminonitriles as bioavailable peptidomimetic inhibitors of cathepsin B","volume":"13","author":"Greenspan","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.08.079_bib69","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1021\/jm0301078","article-title":"A\u00a0novel class of nonpeptidic biaryl inhibitors of human cathepsin K","volume":"46","author":"Robichaud","year":"2003","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib70","doi-asserted-by":"crossref","first-page":"7520","DOI":"10.1021\/jm058198r","article-title":"Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K","volume":"48","author":"Palmer","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib71","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.1021\/jm020209i","article-title":"Design and synthesis of dipeptide nitriles as reversible and potent Cathepsin S inhibitors","volume":"45","author":"Ward","year":"2002","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib72","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.bmcl.2007.12.047","article-title":"The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K","volume":"18","author":"Gauthier","year":"2008","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.08.079_bib73","first-page":"669","article-title":"Merck &Co. drops osteoporosis drug odanacatib","volume":"15","author":"Mullard","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2018.08.079_bib74","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1039\/c2ob00034b","article-title":"Tuning and predicting biological affinity: aryl nitriles as cysteine protease inhibitors","volume":"10","author":"Ehmke","year":"2012","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib75","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1021\/jm070760l","article-title":"Development of potent purine-derived nitrile inhibitors of the trypanosomal protease TbcatB","volume":"51","author":"Mallari","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib76","doi-asserted-by":"crossref","first-page":"5833","DOI":"10.1021\/jm0493111","article-title":"Novel purine nitrile derived inhibitors of the cysteine protease cathepsin K","volume":"47","author":"Altmann","year":"2004","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib77","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003916","article-title":"Molecular design, synthesis and trypanocidal activity of dipeptidyl nitriles as cruzain inhibitors","volume":"9","author":"Avelar","year":"2015","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2018.08.079_bib78","doi-asserted-by":"crossref","first-page":"7688","DOI":"10.1021\/jm050686b","article-title":"Interaction of papain-like cysteine proteases with dipeptide-derived nitriles","volume":"48","author":"L\u00f6ser","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0005343","article-title":"Anti-trypanosomal activity of non-peptidic nitrile-based cysteine protease inhibitors","volume":"11","author":"Burtoloso","year":"2017","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2018.08.079_bib80","doi-asserted-by":"crossref","first-page":"8827","DOI":"10.1021\/jm301119s","article-title":"Pharmacokinetic benefits of 3,4-dimethoxy substitution of a phenyl ring and design of isosteres yielding orally available cathepsin K inhibitors","volume":"55","author":"Crawford","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib81","doi-asserted-by":"crossref","first-page":"6363","DOI":"10.1021\/jm3007257","article-title":"(1R,2R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritis","volume":"55","author":"Dossetter","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib82","doi-asserted-by":"crossref","first-page":"6404","DOI":"10.1021\/ja710254m","article-title":"Identification of a new class of nonpeptidic inhibitors of cruzain","volume":"130","author":"Brak","year":"2008","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2018.08.079_bib83","doi-asserted-by":"crossref","first-page":"15521","DOI":"10.1021\/ja0547230","article-title":"Substrate Activity Screening: a fragment-based method for the rapid identification of nonpeptidic protease inhibitors","volume":"127","author":"Wood","year":"2005","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2018.08.079_bib84","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1021\/jm901633v","article-title":"Nonpeptidic tetrafluorophenoxymethyl ketone cruzain inhibitors as promising new leads for Chagas Disease chemotherapy","volume":"53","author":"Brak","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib85","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1016\/j.bmcl.2015.06.066","article-title":"Tetrafluorophenoxymethyl ketone cruzain inhibitors with improved pharmacokinetic properties as therapeutic leads for Chagas' disease","volume":"25","author":"Neitz","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.08.079_bib86","doi-asserted-by":"crossref","first-page":"7110","DOI":"10.1021\/jo061160h","article-title":"Asymmetric synthesis of \u03b1,\u03b1-dibranched propargylamines by acetylide additions to N-tert-Butanesulfinyl ketimines","volume":"71","author":"Patterson","year":"2006","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib87","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.bmc.2017.02.009","article-title":"Synthesis and biological evaluation of potential inhibitors of the cysteine proteases cruzain and rhodesain designed by molecular simplification","volume":"25","author":"Braga","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib88","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1021\/jm100488w","article-title":"Complementarity between a docking and a high-throughput screen in discovering new cruzain inhibitors","volume":"53","author":"Ferreira","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib89","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1021\/jm0108707","article-title":"Novel short chain chloroquine analogues retain activity against chloroquine resistant K1 Plasmodium falciparum","volume":"45","author":"Stocks","year":"2002","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib90","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1016\/j.ejmech.2010.05.046","article-title":"Design and synthesis of chloroquine analogs with anti-breast cancer property","volume":"45","author":"Solomon","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.079_bib91","doi-asserted-by":"crossref","first-page":"7059","DOI":"10.1016\/j.bmcl.2010.09.107","article-title":"Synthesis of new 4-aminoquinolines and quinoline-acridine hybrids as antimalarial agents","volume":"20","author":"Kumar","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.08.079_bib92","doi-asserted-by":"crossref","first-page":"641","DOI":"10.4155\/fmc-2016-0236","article-title":"Molecular modeling and structure\u2013activity relationships for a series of benzimidazole derivatives as cruzain inhibitors","volume":"9","author":"Pauli","year":"2017","journal-title":"Future Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418307517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418307517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:02:05Z","timestamp":1759327325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523418307517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":92,"alternative-id":["S0223523418307517"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.08.079","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and structure-activity relationship studies of cruzain and rhodesain inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.08.079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}